Commentary on “A novel treatment strategy for newly diagnosed high-grade T1 bladder cancer: Gemcitabine and cisplatin adjuvant chemotherapy—A single-institution experience.”

2018 ◽  
Vol 36 (7) ◽  
pp. 346-347
Author(s):  
GL Yang ◽  
LH Zhang ◽  
Q Liu ◽  
ZL Wang ◽  
XH Duan ◽  
...  
2010 ◽  
Vol 57 (1) ◽  
pp. 60-70 ◽  
Author(s):  
Girish S. Kulkarni ◽  
Oliver W. Hakenberg ◽  
Juergen E. Gschwend ◽  
George Thalmann ◽  
Wassim Kassouf ◽  
...  

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Yoshihisa Kawai ◽  
Fan Zhang ◽  
Shusuke Akamatsu ◽  
Tetsutaro Hayashi ◽  
Kenjiro Imada ◽  
...  

2018 ◽  
Vol 74 (5) ◽  
pp. 597-608 ◽  
Author(s):  
Zachary Klaassen ◽  
Ashish M. Kamat ◽  
Wassim Kassouf ◽  
Paolo Gontero ◽  
Humberto Villavicencio ◽  
...  

Author(s):  
Francesco Morra ◽  
Francesco Merolla ◽  
Daniela Criscuolo ◽  
Luigi Insabato ◽  
Riccardo Giannella ◽  
...  

1986 ◽  
Vol 77 (3) ◽  
pp. 466-473
Author(s):  
Yasunari Uekado ◽  
Toshiaki Shinka ◽  
Kosuke Kumeda ◽  
Atsuyuki Hirano ◽  
Masanori Yoshida ◽  
...  

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e21520-e21520
Author(s):  
T. Ramon y Cajal ◽  
J. Mazarico ◽  
A. Lopez Pousa ◽  
M. Quintana ◽  
N. Sala ◽  
...  

e21520 Background: BS are characterised by local spread and recurrence. Controversy remains about local and adjuvant treatment. The objective of this retrospective study was to analyze clinical and pathological prognostic factors influencing the outcome of BS patients. Methods: We analyzed clinicopathological variables, treatment and outcome of 33 BS patients treated at our institution from 1966 to 2007. A single pathologist reviewed pathologic diagnoses. Kaplan Meier method was used to evaluate outcome. Mean age: 44 years (20–82y. Tumor size 57 (0–230) mm. Pathology: 17 cistosarcoma phylodes (CPh), 9 angiosarcoma, 2 extraesqueletical osteosarcoma, 2 fibrosarcomas, 1 liposarcoma, 1 leiomiosarcoma, 1 malignant fibrous histiocitoma (2.9%). Low-grade in 12, high-grade in 15 pts. Mastectomy in all but 8 patients. Adjuvant chemotherapy and radiotherapy in 9 and 7 patients. Pathological stage I- 12%, II- 65%, III- 9%, IV-3% Results: Median follow-up 71 (5–239) months. Median survival 160 months. Survival was 83%, 74% and 59% at 5, 10 and 15 year. 5/8 (62.5%) local excision patients needed rescue surgery due to local progression. 8/25 (32%) mastectomy patients progressed Local recurrence in 9 pts, distant 4 pts (radical rescue surgery in 10 pts). 7 pts death only 1 phyllodes. Mean 15-year survival for CPh was 169 vs 124 months for other histologies (p 0.06). In the univariate analysis we didn't found statistical differences according to clinical & pathological factors, stage and recurrence, on OS or PFS. Conclusions: CPh have better prognosis than other BS although its stage or size tends to be higher. Radical surgery in BS should be always considered as first treatment option. High-grade non-phylodes BS types may be considered for adjuvant chemotherapy although there were non-statistical differences in OS. No significant financial relationships to disclose.


Sign in / Sign up

Export Citation Format

Share Document